4 completed, 2 unknown, 1 terminated, 1 withdrawn. 5 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Unknown 1, Withdrawn 1 |
Follow Vaxxinity, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants VXX-401, Placebo - Hypercholesterolemia | Phase 1 | Unknown | Vaxxinity, Inc. | 64 | 2023-03-07 | 2023-10-12 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants UB-313, Placebo - Migraine | Phase 1 | Completed | Vaxxinity, Inc. | 40 | 2022-07-06 | 2025-03-12 |
| Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine - COVID-19 Vaccines | Phase 3 | Unknown | Vaxxinity, Inc. | 944 | 2022-03-16 | 2022-10-14 |
| A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine UB-612 - COVID-19 | Phase 1 | Completed | United Biomedical Inc., Asia | 50 | 2021-08-05 | 2022-08-26 |
| A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine UB-612, Placebo - Covid-19, SARS-CoV-2 | Phase 2 / Phase 3 | Withdrawn | Vaxxinity, Inc. | 2021-02-01 | 2022-04-04 | |
| A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers UB-612, Placebo - COVID-19 | Phase 2 | Terminated | United Biomedical Inc., Asia | 3877 | 2021-01-30 | 2022-08-26 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine UB-612 - COVID-19 | Phase 1 | Completed | United Biomedical Inc., Asia | 60 | 2020-09-25 | 2022-08-26 |
| Study of UB-312 in Healthy Participants and Parkinson's Disease Patients UB-312, Placebo - Parkinson's Disease, Parkinsonism | Phase 1 | Completed | United Neuroscience Ltd. | 70 | 2019-08-29 | 2025-03-06 |
COVID-19 (5) · Coronavirus Infections (1) · Hypercholesterolemia (1) · Migraine Disorders (1) · Parkinson Disease (1) · Parkinsonian Disorders (1)
UB-612 COVID-19 vaccine (5) · BIBP COVID-19 vaccine (1) · BNT162 Vaccine (1)
Taiwan (3) · Australia (1) · Belgium (1) · Netherlands (1) · Panama (1) · Philippines (1) · United States (1)
Chang-Yi Wang, Ph.D. (2) · Chang-Yi Wang, Ph.D (1) · Gray Heppner (1) · Sasha Rumyantsev (1)
PMID 35316221, PMID 37079651, PMID 35426173, PMID 38902546, PMID 40727012